PROSTATE SPECIFIC ANTIGEN AND PROSTATE ACID PHOSPHATASE DECLINES AFTER ESTRAMUSTINE PHOSPHATE WITHDRAWAL: A CASE REPORT
- 1 December 1994
- journal article
- case report
- Published by Wiley in International Journal of Urology
- Vol. 1 (4) , 355-356
- https://doi.org/10.1111/j.1442-2042.1994.tb00065.x
Abstract
We report a case of advanced prostate cancer in which an initial response to hormonal therapy with surgical castration and estramustine phosphate (EMP) was followed by disease progression, as shown by sequential elevations in serum prostate specific antigen (PSA) and prostate acid phosphatase (PAP) and the development of new symptoms, during maintenance endocrine and anti-cancer chemotherapy. Discontinuation of EMP resulted in sustained reductions in serum PSA and PAP levels and a sustained improvement in symptoms.Keywords
This publication has 8 references indexed in Scilit:
- Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination TherapyJournal of Urology, 1993
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal SyndromeJournal of Urology, 1993
- Estramustine phosphate and other cytotoxic drugs in the treatment of poor prognostic advanced prostate cancerThe Prostate, 1992
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990
- Tamoxifen withdrawal response. Report of a caseArchives of internal medicine (1960), 1989
- A Comparison of Estramustine Phosphate and Streptozotocin in Patients with Advanced Prostatic Carcinoma Who Have Had Extensive IrradiationJournal of Urology, 1977
- Treatment of Advanced Prostatic Carcinoma with Estracyt: A Preliminary ReportScandinavian Journal of Urology and Nephrology, 1971